TAK - Takeda seeks licensing deal for blood cancer therapy
2024-06-14 08:27:50 ET
More on Takeda Pharmaceutical
- Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk
- Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation
- Pfizer, Takeda say four-year data support Adcetris as Hodgkin lymphoma treatment
- Takeda gets positive opinion from EU regulators for cTTP therapy